Literature DB >> 30328654

Machine learning-based phenogrouping in heart failure to identify responders to cardiac resynchronization therapy.

Maja Cikes1, Sergio Sanchez-Martinez2, Brian Claggett3, Nicolas Duchateau4, Gemma Piella2, Constantine Butakoff2, Anne Catherine Pouleur5, Dorit Knappe6, Tor Biering-Sørensen3,7, Valentina Kutyifa8, Arthur Moss8, Kenneth Stein9, Scott D Solomon3, Bart Bijnens2,10.   

Abstract

AIMS: We tested the hypothesis that a machine learning (ML) algorithm utilizing both complex echocardiographic data and clinical parameters could be used to phenogroup a heart failure (HF) cohort and identify patients with beneficial response to cardiac resynchronization therapy (CRT). METHODS AND
RESULTS: We studied 1106 HF patients from the Multicenter Automatic Defibrillator Implantation Trial with Cardiac Resynchronization Therapy (MADIT-CRT) (left ventricular ejection fraction ≤ 30%, QRS ≥ 130 ms, New York Heart Association class ≤ II) randomized to CRT with a defibrillator (CRT-D, n = 677) or an implantable cardioverter defibrillator (ICD, n = 429). An unsupervised ML algorithm (Multiple Kernel Learning and K-means clustering) was used to categorize subjects by similarities in clinical parameters, and left ventricular volume and deformation traces at baseline into mutually exclusive groups. The treatment effect of CRT-D on the primary outcome (all-cause death or HF event) and on volume response was compared among these groups. Our analysis identified four phenogroups, significantly different in the majority of baseline clinical characteristics, biomarker values, measures of left and right ventricular structure and function and the primary outcome occurrence. Two phenogroups included a higher proportion of known clinical characteristics predictive of CRT response, and were associated with a substantially better treatment effect of CRT-D on the primary outcome [hazard ratio (HR) 0.35; 95% confidence interval (CI) 0.19-0.64; P = 0.0005 and HR 0.36; 95% CI 0.19-0.68; P = 0.001] than observed in the other groups (interaction P = 0.02).
CONCLUSIONS: Our results serve as a proof-of-concept that, by integrating clinical parameters and full heart cycle imaging data, unsupervised ML can provide a clinically meaningful classification of a phenotypically heterogeneous HF cohort and might aid in optimizing the rate of responders to specific therapies.
© 2018 The Authors. European Journal of Heart Failure © 2018 European Society of Cardiology.

Entities:  

Keywords:  Cardiac resynchronization therapy; Echocardiography; Heart failure; Machine learning; Personalized medicine

Mesh:

Year:  2018        PMID: 30328654     DOI: 10.1002/ejhf.1333

Source DB:  PubMed          Journal:  Eur J Heart Fail        ISSN: 1388-9842            Impact factor:   15.534


  46 in total

Review 1.  [Artificial intelligence in cardiology : Relevance, current applications, and future developments].

Authors:  Bettina Zippel-Schultz; Carsten Schultz; Dirk Müller-Wieland; Andrew B Remppis; Martin Stockburger; Christian Perings; Thomas M Helms
Journal:  Herzschrittmacherther Elektrophysiol       Date:  2021-01-15

Review 2.  Artificial Intelligence and Machine Learning in Arrhythmias and Cardiac Electrophysiology.

Authors:  Albert K Feeny; Mina K Chung; Anant Madabhushi; Zachi I Attia; Maja Cikes; Marjan Firouznia; Paul A Friedman; Matthew M Kalscheur; Suraj Kapa; Sanjiv M Narayan; Peter A Noseworthy; Rod S Passman; Marco V Perez; Nicholas S Peters; Jonathan P Piccini; Khaldoun G Tarakji; Suma A Thomas; Natalia A Trayanova; Mintu P Turakhia; Paul J Wang
Journal:  Circ Arrhythm Electrophysiol       Date:  2020-07-06

3.  Machine Learning Prediction of Response to Cardiac Resynchronization Therapy: Improvement Versus Current Guidelines.

Authors:  Albert K Feeny; John Rickard; Divyang Patel; Saleem Toro; Kevin M Trulock; Carolyn J Park; Michael A LaBarbera; Niraj Varma; Mark J Niebauer; Sunil Sinha; Eiran Z Gorodeski; Richard A Grimm; Xinge Ji; John Barnard; Anant Madabhushi; David D Spragg; Mina K Chung
Journal:  Circ Arrhythm Electrophysiol       Date:  2019-06-20

4.  Machine Learning of 12-Lead QRS Waveforms to Identify Cardiac Resynchronization Therapy Patients With Differential Outcomes.

Authors:  Albert K Feeny; John Rickard; Kevin M Trulock; Divyang Patel; Saleem Toro; Laurie Ann Moennich; Niraj Varma; Mark J Niebauer; Eiran Z Gorodeski; Richard A Grimm; John Barnard; Anant Madabhushi; Mina K Chung
Journal:  Circ Arrhythm Electrophysiol       Date:  2020-06-14

5.  Association of Machine Learning-Derived Phenogroupings of Echocardiographic Variables with Heart Failure in Stable Coronary Artery Disease: The Heart and Soul Study.

Authors:  Rakesh K Mishra; Geoffrey H Tison; Qizhi Fang; Rebecca Scherzer; Mary A Whooley; Nelson B Schiller
Journal:  J Am Soc Echocardiogr       Date:  2020-01-14       Impact factor: 5.251

Review 6.  Applications of artificial intelligence in cardiovascular imaging.

Authors:  Maxime Sermesant; Hervé Delingette; Hubert Cochet; Pierre Jaïs; Nicholas Ayache
Journal:  Nat Rev Cardiol       Date:  2021-03-12       Impact factor: 32.419

Review 7.  Machine Learning in Arrhythmia and Electrophysiology.

Authors:  Natalia A Trayanova; Dan M Popescu; Julie K Shade
Journal:  Circ Res       Date:  2021-02-18       Impact factor: 17.367

8.  Generalizability of heterogeneous treatment effects based on causal forests applied to two randomized clinical trials of intensive glycemic control.

Authors:  Sridharan Raghavan; Kevin Josey; Gideon Bahn; Domenic Reda; Sanjay Basu; Seth A Berkowitz; Nicholas Emanuele; Peter Reaven; Debashis Ghosh
Journal:  Ann Epidemiol       Date:  2021-07-17       Impact factor: 3.797

Review 9.  Towards precision medicine in heart failure.

Authors:  Chad S Weldy; Euan A Ashley
Journal:  Nat Rev Cardiol       Date:  2021-06-09       Impact factor: 32.419

10.  The year in cardiovascular medicine 2020: digital health and innovation.

Authors:  Charalambos Antoniades; Folkert W Asselbergs; Panos Vardas
Journal:  Eur Heart J       Date:  2021-02-14       Impact factor: 29.983

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.